DOC News March 1, 2006
Volume 3 Number 3 p. 18
© 2006 American Diabetes Association
Once-Daily Dose Improves Compliance
Compliance with diabetes drug therapy is much higher among patients taking
a once-daily formulation of sulfonylureas, according to a study reported in
the December 2005 issue of Diabetes, Obesity, and
Metabolism.
The project included 105 patients with type 2 diabetes, 40–75 years
of age, who had taken a sulfonylurea drug.
Participants were randomized to receive twice-daily doses of glibenclamide,
while the rest took a once-daily dose of sustained-release gliclazide. They
took the drug for 16 weeks, using a special tablet bottle equipped with a
microprocessor to keep track of the date and time when medication is
taken.
People prescribed the once-daily drug complied much more often, took the
correct number of doses on more days, and missed doses less often than those
on the twice-daily regimen. Those who took the once-daily drug also had better
blood glucose results and lower glycated hemoglobin (A1C).
Kardas P: The DIACOM study (effect of DosIng frequency of
oral Antidiabetic agents on the COMpliance and biochemical control of type 2
diabetes). Diabetes Obes Metab 7: 722–728, 2005[Medline].
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
